The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Hyun Cheol Chung(Yonsei University), Kohei Shitara(National Cancer Center Hospital East), Lie Li(Qingdao University), О. P. Коlesnik, Olga Barajas(Fundación Arturo López Pérez), Patricio Yañez(Universidad de La Frontera), Sara Lonardi(Istituto Oncologico Veneto), Akihito Kawazoe(National Cancer Center Hospital East), Shukui Qin(Memorial Sloan Kettering Cancer Center), Yong Tang(Xinjiang Medical University), Yuxian Bai(Harbin Medical University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Ning Li(Zhengzhou University), Lin Shen(Hangzhou Normal University), Jianming Xu(Chinese PLA General Hospital), Sukrut Shah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Josep Tabernero(Deaconess Hospital)
Cited by 687
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k